E-drug: Economics of antiretroviral manufacturing (cont'd)
-----------------------------------------------------
In reaction to the E-drug contribution of Chris Green on production of
ARV drugs in developing countries, I believe his reasoning is correct
and I can add the "know-how" as another element necessary for
production. This may be a very costly aspect here.
From a PHC point of view the approach to prevent HIV-infection is still
priority policy in developing countries. By investing more in this
approach, results may become better.
On the other hand I am surprised that minimal or no discussion is
taking place in developing countries themselves on how to make
ARV-drugs available to the people. Is it another burden when most
essential drugs are not available anyway?
I think that availability of ARV drugs is in principle not a different
problem than general availability of essential drugs. And we know about
the policy and options of that problem, as we work on it every day. It
should be treated no different, I think. Which would mean that
discussions should take place to add the drugs in the Essential Drug
Lists or not, etc..
Best regards,
Rob Verhage
Procurement Advisor
Ministry of Health
Accra, Ghana
E-mail: 106573.3254@compuserve.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.